[
  {
    "ts": "2025-12-03T06:57:43+00:00",
    "headline": "Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]",
    "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-price-target-065743427.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fa6949cb-c27d-3ac9-b4a8-de920848303d",
      "content": {
        "id": "fa6949cb-c27d-3ac9-b4a8-de920848303d",
        "contentType": "STORY",
        "title": "Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates",
        "description": "",
        "summary": "Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S […]",
        "pubDate": "2025-12-03T06:57:43Z",
        "displayTime": "2025-12-03T06:57:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed",
          "originalWidth": 158,
          "originalHeight": 128,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vDyP7pqW3TbUTzh67tIgVg--~B/aD0xMjg7dz0xNTg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed.cf.webp",
              "width": 158,
              "height": 128,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X8b4DTWv677oFnBOijPswg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/52c9c784bf549608e91c2900af16ebed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-price-target-065743427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-price-target-065743427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T11:59:00+00:00",
    "headline": "Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
    "summary": "PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-continuation-115900419.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "1e46a077-2154-3f54-bde5-a0e1b4c767ff",
      "content": {
        "id": "1e46a077-2154-3f54-bde5-a0e1b4c767ff",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
        "description": "",
        "summary": "PRINCETON, N.J., December 03, 2025--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease",
        "pubDate": "2025-12-03T11:59:00Z",
        "displayTime": "2025-12-03T11:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b",
          "originalWidth": 1497,
          "originalHeight": 206,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MzAjeCdTFYKdKShe_uF.tA--~B/aD0yMDY7dz0xNDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b.cf.webp",
              "width": 1497,
              "height": 206,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuF.CGfK_YlYk3ska5RfAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/37b8ce39cd94dc9a4e604f72ddc75a2b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-continuation-115900419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-announces-continuation-115900419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T14:54:39+00:00",
    "headline": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
    "summary": "Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.",
    "url": "https://www.investors.com/news/technology/bristol-myers-squibb-stock-cobenfy-delay/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "7bc72dad-21ef-3489-816e-7be9bcef08d3",
      "content": {
        "id": "7bc72dad-21ef-3489-816e-7be9bcef08d3",
        "contentType": "STORY",
        "title": "Why A Surprise Delay For Cobenfy Just Sparked Bristol Myers Stock",
        "description": "",
        "summary": "Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.",
        "pubDate": "2025-12-03T14:54:39Z",
        "displayTime": "2025-12-03T14:54:39Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7bc72dad-21ef-3489-816e-7be9bcef08d3/why-a-surprise-delay-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/b3c70d96a5ada9e95a50869c3a4f3722",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j3JTvymRHXIlwun6knekJg--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/b3c70d96a5ada9e95a50869c3a4f3722.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w6QlyKN7KTGdJM6jEvgiQQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/b3c70d96a5ada9e95a50869c3a4f3722.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/bristol-myers-squibb-stock-cobenfy-delay/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T14:16:00+00:00",
    "headline": "Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.",
    "summary": "The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.",
    "url": "https://www.barrons.com/articles/bristol-myers-squibb-alzheimers-trial-cobenfy-37ce479a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "994fd0dc-dae9-35fb-9fcf-03dc087832d2",
      "content": {
        "id": "994fd0dc-dae9-35fb-9fcf-03dc087832d2",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.",
        "description": "",
        "summary": "The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease.",
        "pubDate": "2025-12-03T14:16:00Z",
        "displayTime": "2025-12-03T14:16:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/994fd0dc-dae9-35fb-9fcf-03dc087832d2/bristol-myers-squibb-stock.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/da0aa645234abcac6829d038c81ab124",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kEyVDfXjULqUF2rdUlOa.w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/da0aa645234abcac6829d038c81ab124.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9XNhWPUwSVFPpVWdhiPi4A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/da0aa645234abcac6829d038c81ab124.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/bristol-myers-squibb-alzheimers-trial-cobenfy-37ce479a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T14:00:03+00:00",
    "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-140003218.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "44e94b83-825b-38e6-b722-a2a47483d4af",
      "content": {
        "id": "44e94b83-825b-38e6-b722-a2a47483d4af",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
        "description": "",
        "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
        "pubDate": "2025-12-03T14:00:03Z",
        "displayTime": "2025-12-03T14:00:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2",
          "originalWidth": 900,
          "originalHeight": 469,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FhE.FTVPiyZE7qpXxRqaxQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2.cf.webp",
              "width": 900,
              "height": 469,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sFRv_ZJmMJVPU2zxJKrzAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-140003218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-company-bmy-140003218.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-03T16:00:00+00:00",
    "headline": "Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb",
    "summary": "LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb",
    "url": "https://finance.yahoo.com/news/terray-therapeutics-achieves-ai-enabled-160000443.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fff486df-0daf-3f98-bb6a-4a277407586f",
      "content": {
        "id": "fff486df-0daf-3f98-bb6a-4a277407586f",
        "contentType": "STORY",
        "title": "Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb",
        "description": "",
        "summary": "LOS ANGELES, December 03, 2025--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb",
        "pubDate": "2025-12-03T16:00:00Z",
        "displayTime": "2025-12-03T16:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qzhadu.3IAQU.l0IoiPHew--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.0xPryTNtGueRcCA1piaaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8cfcff908c57e8fac40ee340a28000f3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/terray-therapeutics-achieves-ai-enabled-160000443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/terray-therapeutics-achieves-ai-enabled-160000443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]